|drug16||150 ppm Nitric Oxide delivered through LungFit Delivery System Wiki||1.00|
|drug3111||Web Based Survey Wiki||1.00|
|D012120||Respiration Disorders NIH||0.26|
|D012140||Respiratory Tract Diseases NIH||0.21|
|D011024||Pneumonia, Viral NIH||0.12|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
Description: Time to deterioration as measured by any one of the following: need for non-invasive ventilation need for high flow nasal cannula (HFNC) or need for intubation Death from any causeMeasure: Time to deterioration Time: up to 14 days
Description: Time to patient having stable oxygen saturation (SpO2) of greater than 92% for longer than 3 hr on room airMeasure: Time to stable oxygen saturation Time: up to 14 days
Description: Treatment Emergent Adverse Events and SAEs - safety evaluation for 30 days after last inhalation treatmentMeasure: Treatment Emergent Adverse Events and SAEs Time: 30 days after last inhalation treatment